ABSTRACT

Head and neck squamous cell carcinomas (HNSCC) are the 7th most common cancer worldwide. Docetaxel, cisplatin and 5-fluorouracil (5-FU) are conventional chemo-drugs used for the treatment of head and neck cancer. However, treatment with these chemo-drugs is associated with severe late toxicities and acquired resistance, a major cause of mortality in HNSCC patients. Hence, identification of molecular targets associated with chemo-resistance to develop personalized and effective treatment is required. Bone marrow stromal antigen-2 (BST-2) is a Type-I interferon inducible anti-viral protein expressed on the surface, and in vesicular compartments of host cells. Studies reveal high expression of BST-2 in a large number of cancers like breast cancer, HNSCC, lung cancer, cervical cancer, glioblastoma and myeloma. In breast cancer, over-expression of BST-2 mediates invasion, migration, progression and survival of cells. BST-2 over-expression is also reported to confer resistance to chemo-therapies such as cisplatin and gefitinib in HNSCC. In this study, we report that BST-2 is over-expressed in HNSCC through in-vitro and bioinformatics approaches. Treatment with conventional chemo-drugs increased the levels of BST-2 in the human laryngeal cancer cell line, HEp-2. Treatment with commercially available small molecule inhibitor of the kinase activity of Interleukin-1 receptor associated kinases (IRAK)- 1 and -4, decreased the levels of BST-2 in HEp-2. Our findings suggest BST-2 as a chemo-resistance specific druggable target in
Publication date: 01/06/2023

https://www.ijbpas.com/pdf/2023/June/MS_IJBPAS_2023_7221.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.6.7221